ArticleVeterinary research2026
Seroprevalence and associated risk factors for feline panleukopenia virus infection among managed giant pandas in China.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Feline panleukopenia virus (FPV) poses a significant threat to carnivores worldwide, with increasing documentation of spillover infections in endangered species, including the giant panda (Ailuropoda melanoleuca). Despite the presence of serological evidence indicating historical exposure, contemporary data concerning the prevalence of FPV and the associated risk factors in giant pandas remains limited. This study conducted a comprehensive seroepidemiological survey of 136 giant pandas, representing 262 serum samples, from the Chengdu Research Base of Giant Panda Breeding between 2015 and 2023. The overall seroprevalence of FPV antibodies was 56.87% (149/262, 95% CI 0.51-0.63), with consistently high levels observed across years. Multivariate analysis identified young age and the summer season as protective factors, likely due to maternal-derived antibodies and environmentally mediated reduction in viral persistence, respectively. Although not statistically significant, a transfer history showed a trend toward elevated risk (OR > 1), suggesting that it may still represent a potential risk factor. It is important to note that current vaccination protocols appear to be inadequate in eliciting robust immune responses, thereby underscoring the necessity for the development of tailored vaccines. These findings emphasize the persistent and widespread circulation of FPV in captive giant pandas and advocate for seasonally targeted biosecurity measures, rationalized animal transfer protocols, and enhanced immunization strategies to mitigate infection risks in this vulnerable species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.